Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
CYBX's Cash to Debt is ranked higher than
97% of the 475 Companies
in the Global Medical Devices industry.

( Industry Median: 2.09 vs. CYBX: No Debt )
CYBX' s 10-Year Cash to Debt Range
Min: 0.64   Max: 25573
Current: No Debt

0.64
25573
Equity to Asset 0.91
CYBX's Equity to Asset is ranked higher than
95% of the 447 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. CYBX: 0.91 )
CYBX' s 10-Year Equity to Asset Range
Min: -0.14   Max: 0.94
Current: 0.91

-0.14
0.94
Interest Coverage 4000.60
CYBX's Interest Coverage is ranked higher than
68% of the 262 Companies
in the Global Medical Devices industry.

( Industry Median: 231.38 vs. CYBX: 4000.60 )
CYBX' s 10-Year Interest Coverage Range
Min: 5.59   Max: 9999.99
Current: 4000.6

5.59
9999.99
F-Score: 7
Z-Score: 35.17
M-Score: -2.51
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 32.17
CYBX's Operating margin (%) is ranked higher than
99% of the 459 Companies
in the Global Medical Devices industry.

( Industry Median: 5.91 vs. CYBX: 32.17 )
CYBX' s 10-Year Operating margin (%) Range
Min: -814.29   Max: 30.81
Current: 32.17

-814.29
30.81
Net-margin (%) 21.88
CYBX's Net-margin (%) is ranked higher than
96% of the 459 Companies
in the Global Medical Devices industry.

( Industry Median: 4.15 vs. CYBX: 21.88 )
CYBX' s 10-Year Net-margin (%) Range
Min: -800   Max: 46.76
Current: 21.88

-800
46.76
ROE (%) 24.86
CYBX's ROE (%) is ranked higher than
97% of the 445 Companies
in the Global Medical Devices industry.

( Industry Median: 5.20 vs. CYBX: 24.86 )
CYBX' s 10-Year ROE (%) Range
Min: -226.26   Max: 581.59
Current: 24.86

-226.26
581.59
ROA (%) 22.29
CYBX's ROA (%) is ranked higher than
98% of the 475 Companies
in the Global Medical Devices industry.

( Industry Median: 2.77 vs. CYBX: 22.29 )
CYBX' s 10-Year ROA (%) Range
Min: -158.87   Max: 58.59
Current: 22.29

-158.87
58.59
ROC (Joel Greenblatt) (%) 97.19
CYBX's ROC (Joel Greenblatt) (%) is ranked higher than
98% of the 473 Companies
in the Global Medical Devices industry.

( Industry Median: 9.15 vs. CYBX: 97.19 )
CYBX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -6933.33   Max: 116.28
Current: 97.19

-6933.33
116.28
Revenue Growth (%) 15.50
CYBX's Revenue Growth (%) is ranked higher than
89% of the 341 Companies
in the Global Medical Devices industry.

( Industry Median: 5.00 vs. CYBX: 15.50 )
CYBX' s 10-Year Revenue Growth (%) Range
Min: 1.5   Max: 180.6
Current: 15.5

1.5
180.6
EBITDA Growth (%) 19.50
CYBX's EBITDA Growth (%) is ranked higher than
90% of the 314 Companies
in the Global Medical Devices industry.

( Industry Median: 1.60 vs. CYBX: 19.50 )
CYBX' s 10-Year EBITDA Growth (%) Range
Min: -54.6   Max: 26.3
Current: 19.5

-54.6
26.3
EPS Growth (%) 7.10
CYBX's EPS Growth (%) is ranked higher than
79% of the 298 Companies
in the Global Medical Devices industry.

( Industry Median: 3.60 vs. CYBX: 7.10 )
CYBX' s 10-Year EPS Growth (%) Range
Min: -38.2   Max: 11.2
Current: 7.1

-38.2
11.2
» CYBX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

CYBX Guru Trades in Q4 2013

RS Investment Management 912,588 sh (+48.88%)
Paul Tudor Jones Sold Out
Jim Simons 2,310,094 sh (-6.32%)
John Hussman 355,000 sh (-30.26%)
Joel Greenblatt 5,079 sh (-31.21%)
Steven Cohen 11,957 sh (-92.79%)
» More
Q1 2014

CYBX Guru Trades in Q1 2014

Paul Tudor Jones 6,500 sh (New)
RS Investment Management 1,266,459 sh (+38.78%)
Joel Greenblatt 5,096 sh (+0.33%)
Jim Simons 2,223,194 sh (-3.76%)
John Hussman 266,000 sh (-25.07%)
Steven Cohen 6,700 sh (-43.97%)
» More
Q2 2014

CYBX Guru Trades in Q2 2014

Joel Greenblatt 20,851 sh (+309.16%)
Jim Simons 2,411,201 sh (+8.46%)
Paul Tudor Jones 6,400 sh (-1.54%)
RS Investment Management 1,023,829 sh (-19.16%)
John Hussman 200,000 sh (-24.81%)
» More
Q3 2014

CYBX Guru Trades in Q3 2014

Joel Greenblatt 170,735 sh (+718.83%)
Paul Tudor Jones 15,400 sh (+140.63%)
RS Investment Management 979,879 sh (-4.29%)
Jim Simons 2,271,794 sh (-5.78%)
John Hussman 75,000 sh (-62.5%)
» More
» Details

Insider Trades

Latest Guru Trades with CYBX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Hussman 2014-09-30 Reduce -62.5%0.6%$50.31 - $62.61 $ 54.65-5%75000
Joel Greenblatt 2014-09-30 Add 718.83%0.08%$50.31 - $62.61 $ 54.65-5%170735
John Hussman 2014-06-30 Reduce -24.81%0.32%$57.14 - $65.99 $ 54.65-10%200000
Joel Greenblatt 2014-06-30 Add 309.16%0.01%$57.14 - $65.99 $ 54.65-10%20851
John Hussman 2014-03-31 Reduce -25.07%0.43%$62 - $72.98 $ 54.65-19%266000
John Hussman 2013-12-31 Reduce -30.26%0.42%$50.84 - $71.5 $ 54.65-10%355000
Joel Greenblatt 2013-12-31 Reduce -31.21%$50.84 - $71.5 $ 54.65-10%5079
Joel Greenblatt 2013-09-30 Reduce -26.68%0.01%$50.51 - $56 $ 54.654%7383
John Hussman 2013-06-30 Reduce -41.87%0.63%$42.97 - $52.54 $ 54.6515%522000
Joel Greenblatt 2013-06-30 Reduce -23.68%0.01%$42.97 - $52.54 $ 54.6515%10070
Joel Greenblatt 2013-03-31 Add 113.1%0.02%$42.73 - $55.42 $ 54.6515%13195
Joel Greenblatt 2012-12-31 New Buy0.02%$44.5 - $53.23 $ 54.659%6192
Joel Greenblatt 2012-03-31 Sold Out 0.05%$32.18 - $39.01 $ 54.6567%0
Joel Greenblatt 2011-12-31 Reduce -24.38%0.02%$26.93 - $34.2 $ 54.6584%12604
Carl Icahn 2011-09-30 Sold Out 0.98%$23.7 - $30 $ 54.65100%0
Joel Greenblatt 2011-09-30 Add 27.85%0.02%$23.7 - $30 $ 54.65100%16667
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 23.50
CYBX's P/E(ttm) is ranked higher than
89% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 85.90 vs. CYBX: 23.50 )
CYBX' s 10-Year P/E(ttm) Range
Min: 6.15   Max: 219.29
Current: 23.5

6.15
219.29
P/B 5.35
CYBX's P/B is ranked higher than
63% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 3.88 vs. CYBX: 5.35 )
CYBX' s 10-Year P/B Range
Min: 3.92   Max: 180.33
Current: 5.35

3.92
180.33
P/S 5.12
CYBX's P/S is ranked higher than
64% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 3.41 vs. CYBX: 5.12 )
CYBX' s 10-Year P/S Range
Min: 2.16   Max: 10.82
Current: 5.12

2.16
10.82
PFCF 22.96
CYBX's PFCF is ranked higher than
91% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. CYBX: 22.96 )
CYBX' s 10-Year PFCF Range
Min: 10   Max: 1235.33
Current: 22.96

10
1235.33
EV-to-EBIT 13.91
CYBX's EV-to-EBIT is ranked higher than
93% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 64.69 vs. CYBX: 13.91 )
CYBX' s 10-Year EV-to-EBIT Range
Min: -111   Max: 309.6
Current: 13.91

-111
309.6
PEG 1.07
CYBX's PEG is ranked higher than
97% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. CYBX: 1.07 )
CYBX' s 10-Year PEG Range
Min: 0.74   Max: 1.85
Current: 1.07

0.74
1.85
Shiller P/E 29.18
CYBX's Shiller P/E is ranked higher than
91% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. CYBX: 29.18 )
CYBX' s 10-Year Shiller P/E Range
Min: 26.74   Max: 214.29
Current: 29.18

26.74
214.29
Current Ratio 8.78
CYBX's Current Ratio is ranked higher than
93% of the 467 Companies
in the Global Medical Devices industry.

( Industry Median: 2.79 vs. CYBX: 8.78 )
CYBX' s 10-Year Current Ratio Range
Min: 0.81   Max: 15.71
Current: 8.78

0.81
15.71
Quick Ratio 8.03
CYBX's Quick Ratio is ranked higher than
93% of the 467 Companies
in the Global Medical Devices industry.

( Industry Median: 2.01 vs. CYBX: 8.03 )
CYBX' s 10-Year Quick Ratio Range
Min: 0.69   Max: 15.35
Current: 8.03

0.69
15.35

Valuation & Return

vs
industry
vs
history
Price/Net Cash 12.56
CYBX's Price/Net Cash is ranked higher than
91% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. CYBX: 12.56 )
CYBX' s 10-Year Price/Net Cash Range
Min: 5.63   Max: 136.76
Current: 12.56

5.63
136.76
Price/Net Current Asset Value 8.97
CYBX's Price/Net Current Asset Value is ranked higher than
88% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. CYBX: 8.97 )
CYBX' s 10-Year Price/Net Current Asset Value Range
Min: 5.26   Max: 675
Current: 8.97

5.26
675
Price/Tangible Book 5.58
CYBX's Price/Tangible Book is ranked higher than
73% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 6.71 vs. CYBX: 5.58 )
CYBX' s 10-Year Price/Tangible Book Range
Min: 2.02   Max: 178.58
Current: 5.58

2.02
178.58
Price/DCF (Projected) 1.58
CYBX's Price/DCF (Projected) is ranked higher than
92% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. CYBX: 1.58 )
CYBX' s 10-Year Price/DCF (Projected) Range
Min: 1.52   Max: 93.7
Current: 1.58

1.52
93.7
Price/Median PS Value 1.09
CYBX's Price/Median PS Value is ranked higher than
76% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 1.20 vs. CYBX: 1.09 )
CYBX' s 10-Year Price/Median PS Value Range
Min: 0.53   Max: 20.16
Current: 1.09

0.53
20.16
Price/Peter Lynch Fair Value 1.06
CYBX's Price/Peter Lynch Fair Value is ranked higher than
99% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. CYBX: 1.06 )
CYBX' s 10-Year Price/Peter Lynch Fair Value Range
Min: 1.02   Max: 2.79
Current: 1.06

1.02
2.79
Price/Graham Number 2.38
CYBX's Price/Graham Number is ranked higher than
85% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. CYBX: 2.38 )
CYBX' s 10-Year Price/Graham Number Range
Min: 1.05   Max: 10.89
Current: 2.38

1.05
10.89
Earnings Yield (Greenblatt) 7.20
CYBX's Earnings Yield (Greenblatt) is ranked higher than
93% of the 469 Companies
in the Global Medical Devices industry.

( Industry Median: 2.40 vs. CYBX: 7.20 )
CYBX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.3   Max: 8.1
Current: 7.2

0.3
8.1
Forward Rate of Return (Yacktman) 25.58
CYBX's Forward Rate of Return (Yacktman) is ranked higher than
94% of the 213 Companies
in the Global Medical Devices industry.

( Industry Median: 5.50 vs. CYBX: 25.58 )
CYBX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -8   Max: 39
Current: 25.58

-8
39

Analyst Estimate

Apr15 Apr16 Apr17
Revenue(Mil) 295 322 343
EPS($) 2.39 2.68 2.88
EPS without NRI($) 2.39 2.68 2.88

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:JC8.Germany,
Cyberonics, Inc. was incorporated in the state of Delaware in 1987. The Company is a medical device company. It is engaged in the design, development, sales and marketing of implantable medical devices that provide vagus nerve stimulation therapy (VNS Therapy), for the treatment of refractory epilepsy and treatment-resistant depression. The Company's proprietary VNS Therapy System includes: An implantable pulse generator to provide stimulation to the vagus nerve; A lead that connects the generator to the vagus nerve; Equipment to assist with the implant procedure; Equipment to assist the treating physician with setting the stimulation parameters for each patient; Instruction manuals; and Magnets to temporarily suspend or induce stimulation manually. The VNS Therapy pulse generator and lead are surgically implanted into patients generally during an outpatient procedure. The battery contained in the generator has a finite life, which varies according to the model as well as the stimulation parameters for each patient. At or near the end of the useful life of a battery, a patient may, with the advice of a physician, choose to implant a new generator, which may be done with or without replacing the original lead. The Company sells the VNS Therapy System to hospitals and ambulatory surgery centers (ASCs) on payment terms that are generally 30 days from the shipment date. The Company's medical devices are subject to regulation by numerous government agencies, including the FDA and comparable foreign agencies.
» More Articles for CYBX

Headlines

Articles On GuruFocus.com
comment on CYBX Feb 24 2013 
comment on CYBX Jan 26 2013 
Cyberonics Inc. (CYBX) President & CEO Daniel Jeffrey Moore sells 44,700 Shares Jan 13 2011 
Cyberonics Inc. (CYBX) VP Finance & CFO Gregory H Browne sells 10,000 Shares Jan 12 2011 
Cyberonics Inc. (CYBX) VP Finance & CFO Gregory H Browne sells 5,000 Shares Dec 08 2010 
Cyberonics Inc. Reports Operating Results (10-Q) Nov 22 2010 
Cyberonics Inc. Reports Operating Results (10-Q) Aug 26 2010 
Cyberonics Inc. Reports Operating Results (10-K) Jun 17 2010 
Cyberonics Inc. Reports Operating Results (10-Q) Feb 18 2010 
Cyberonics Inc. Reports Operating Results (10-Q) Nov 19 2009 

More From Other Websites
Cyberonics Announces Resignation Of Milton M. Morris, Senior Vice President, Research & Development Dec 17 2014
Cyberonics Announces Resignation Of Milton M. Morris, Senior Vice President, Research & Development Dec 17 2014
Cyberonics Posts Positive Epilepsy Device Data, Shares Up Dec 10 2014
Cyberonics Reports Consistently Positive Results From The E-36 And E-37 Studies For VNS Therapy... Dec 08 2014
CYBERONICS INC Financials Nov 27 2014
Today's Dead Cat Bounce Stock: Cyberonics (CYBX) Nov 24 2014
Cyberonics To Present At The 26th Annual Piper Jaffray Healthcare Conference Nov 24 2014
Cyberonics To Present At The 26th Annual Piper Jaffray Healthcare Conference Nov 24 2014
Cyberonics Slumps: CYBX Falls 5.1% in Session Nov 24 2014
10-Q for Cyberonics, Inc. Nov 22 2014
Cyberonics (CYBX) Is Today's Perilous Reversal Stock Nov 21 2014
Cyberonics Beats Q2 Earnings, Sales Up, EPS View Retained Nov 21 2014
Cyberonics (CYBX) in Focus: Stock Adds 13.4% in Session Nov 21 2014
Cyberonics (CYBX) Marked As A Barbarian At The Gate Nov 20 2014
Cyberonics beats 2Q profit forecasts Nov 20 2014
Cyberonics beats 2Q profit forecasts Nov 20 2014
Q2 2015 Cyberonics Inc Earnings Release - Before Market Open Nov 20 2014
CYBERONICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Nov 20 2014
Cyberonics Reports Fiscal 2015 Second Quarter Results Nov 20 2014
Cyberonics To Report Fiscal Year 2015 Second Quarter Results And Host Webcast And Conference Call On... Nov 06 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK